News Sarepta shares slide as DMD treatment woes pile up The ESSENCE trial of Sarepta's Vyondys 53 and Amondys 45 failed to hit its objective, placing their FDA accelerated approvals at risk.
R&D Working together to innovate on pragmatic clinical trials, w... In today’s episode, host Jonah Comstock speaks with Rob DiCicco, vice president of portfolio management at TransCelerate Biopharma.
Sales & Marketing Sponsored How to meet your physicians where they are online A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
